Compare · head to head
Apellis Pharmaceuticals vs Incyte
Incyte ranks higher overall — 360 rank 95 vs 75.
Incyte leads on Value (70 vs 53) and Safety (68 vs 60). The two are close on Quality and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Medium | Large |
| ISIN | US03753U1060 | US45337C1027 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 75 | 95 |
| Value | 53 | 70 |
| Quality | 67 | 68 |
| Growth | NR | 56 |
| Safety | 60 | 68 |
| Sentiment | 45 | 44 |
| Quality details | ||
| Profitability | 89 | 84 |
| Cash Truth | 45 | 51 |
Apellis Pharmaceuticals vs SurrozenApellis Pharmaceuticals vs Nurix TherapeuticsApellis Pharmaceuticals vs Kalvista PharmaceuticalsApellis Pharmaceuticals vs Legend BiotechAdd a third stock →
Full analyses: Apellis Pharmaceuticals · Incyte
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100